Meanwhile, we did not detect a substantial difference between dapagliflozin and empagliflozin in clinical outcomes, suggesting the consistent anti–prostate cancer effects within the class of SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and prostate cancer.